Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490907 | 0.87 | MAPK14 (0.45) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4499077 | 0.87 | MAPK14 (0.46) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4510145 | 0.85 | MAPK14 (0.51) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4504173 | 0.83 | GABRA5 (0.48) | MAPK14RAB9AKDM4ENPC1KMT2A | |
| SCHEMBL4500969 | 0.83 | GABRA5 (0.48) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4488302 | 0.83 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4498333 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4489721 | 0.81 | GABRA5 (0.50) | MAPK14 | |
| SCHEMBL4488413 | 0.78 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HPGDMAPK1MAPK14 | |
| SCHEMBL4500494 | 0.77 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2HPGDMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | claimed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | GABRA5, GABRA4, GABRA1 | ALDH1A1 226/4885SMN1; SMN2 3128/4885HPGD 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.